Journal article

Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap

Anthony P Longhitano, Monica A Slavin, Simon J Harrison, Benjamin W Teh



Relapsed haematological malignancies have a poor disease prognosis with current therapies. Bispecific antibodies (BsAbs) are becoming increasingly recognised for their efficacy in the treatment of these malignancies and are approved for the treatment of B-cell acute lymphoblastic leukaemia (B-ALL). BsAbs are manufactured to consist two variable chain fragments combined by a peptide linker amongst other structures to increase the half-life of the molecules. BsAbs function by bringing targeted tumour cells in close proximity of T-cells to allow killing via perforin and granzyme release. The increasing numbers of trials of BsAbs has highlighted their toxicity profile, including cytokine release..

View full abstract


Funding Acknowledgements

The National Centre for Infections in Cancer is a National Health and Medical Research Council (NHMRC) Centre for Research Excellence. MAS is supported by NHMRC Investigator fellowship. BWT is supported by the NHMRC Early Career Fellowship and Medical Research Future Fund Emerging Leader Fellowship.